| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 25,130 | 31,634 | 35,442 | 26,793 |
| Other current assets | 268 | 75 | 145 | 214 |
| Total current assets | 25,398 | 31,709 | 35,587 | 27,007 |
| Total assets | 25,398 | 31,709 | 35,587 | 27,007 |
| Accounts payable | 4,695 | 6,274 | 6,439 | 4,977 |
| Payable offering costs | NaN | NaN | 75 | 75 |
| Accrued liabilities | 36 | 115 | 65 | 2 |
| Employee compensation and benefits | 6,447 | 6,907 | 4,998 | 5,081 |
| Total current liabilities | 11,178 | 13,296 | 11,577 | 10,135 |
| Total liabilities | 11,178 | 13,296 | 11,577 | 10,135 |
| Additional paid in capital | 119,957 | 118,100 | 116,383 | 101,783 |
| Accumulated deficit | -105,737 | -99,687 | -92,373 | -84,911 |
| Total shareholders' equity | 14,220 | 18,413 | 24,010 | 16,872 |
| Total liabilities and shareholders' equity | 25,398 | 31,709 | 35,587 | 27,007 |
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)